A Study of a Levonorgestrel-Releasing Intrauterine System for Long-Term, Reversible Contraception

Not Recruiting

Trial ID: NCT00995150

Purpose

The primary objective of this study is to assess the efficacy of a levonorgestrel-releasing intrauterine system (LNG20) in nulliparous and parous females of child-bearing potential who request long-term, reversible contraception for up to 10 years.

Official Title

A Phase 3, Multi-Center, Open-Label Study of a Levonorgestrel-Releasing Intrauterine System for Long-Term, Reversible Contraception

Stanford Investigator(s)

Paul D. Blumenthal, MD, MPH
Paul D. Blumenthal, MD, MPH

Professor of Obstetrics and Gynecology (Gynecology-Family Planning) at the Stanford University Medical Center, Emeritus

Eligibility

Inclusion Criteria:

* Healthy women requesting contraception
* 16-35 years old
* Cohort 36-45 years old
* Sexually active

Exclusion Criteria:

* Currently pregnant, pregnant within 4 weeks prior to study entry or planning pregnancy within 24 months of study entry
* Currently breastfeeding
* Current persistent, abnormal vaginal bleeding

Intervention(s):

drug: LNG20

drug: Mirena

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Kathryn Batham
650-724-7826